Ikena Oncology, Inc. (IKNA)
Ikena Oncology, Inc.
645 Summer Street
Suite 101
Boston, MA 02210
United States
857 273 8343
https://ikenaoncology.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 43
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Mark Manfredi Ph.D. | President, CEO & Director | 810.69k | N/D | 1971 |
| Dr. Jotin Marango M.D., Ph.D. | CFO & Head of Corporate Development | 577.12k | N/D | 1979 |
| Mr. Bob Lally | Senior Vice President of Finance & Operations | N/D | N/D | N/D |
| Ms. Srividya Subramanian Esq., Ph.D. | VP & Deputy General Counsel | N/D | N/D | N/D |
| Ms. Samantha Vuksanic | Head of Human Resources | N/D | N/D | N/D |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | N/D | N/D | 1970 |
| Mr. Navin Parwani M.S. | VP & Head of Quality | N/D | N/D | N/D |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | N/D | N/D | N/D |
| Dr. Caroline Germa M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1972 |
| Mr. Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations | N/D | N/D | N/D |
Descripción
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Ikena Oncology, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 8; Derechos del accionista: 10; Compensación: 9.
